Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.
J Nucl Med. 2011 Jun;52(6):841-4. doi: 10.2967/jnumed.110.084236. Epub 2011 May 13.
Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [(111)In-diethylenetriaminepentaacetic acid(0)]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as (68)Ga, (64)Cu, and (18)F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with (90)Y and (177)Lu.
放射性标记肽在放射性药物科学和核医学领域已经有 20 多年的历史，是一类重要的化合物。尽管研究工作力度很大，但只有基于生长抑素的放射性肽对患者的诊断和治疗有实际影响。[(111)In-二乙三胺五乙酸(0)]奥曲肽可用于商业成像。通过引入 PET 放射性核素，如(68)Ga、(64)Cu 和(18)F，成像质量得到了极大的提高。当与 DOTA 结合并标记(90)Y 和(177)Lu 时，两种肽成功地用于靶向放射性核素治疗。
